(NP (NP-COOD (NP Aldosterone-specific/JJ membrane/NN receptors/NNS) and/CC (NP (NP rapid/JJ non-genomic/JJ actions/NNS) (PP of/IN (NP mineralocorticoids/NNS)))) ./.)
(S (NP-SBJ (NP Functional/JJ studies/NNS) (PP in/IN (NP (NP (ADJP-COOD (ADJP extrarenal/JJ) ,/, (ADJP non-epithelial/JJ)) cells/NNS) (PP such/JJ as/IN (NP-COOD (NP smooth/JJ muscle/NN cells/NNS) and/CC (NP (ADVP-TMP more/RBR recently/RB) circulating/VBG human/JJ lymphocytes/NNS)))))) (VP have/VBP (VP provided/VBN (NP increasing/VBG evidence/NN (SBAR that/IN (S (NP-SBJ aldosterone/NN) (VP produces/VBZ (NP (NP-COOD (CONJP not/RB only/RB) (NP classical/JJ genomic/JJ effects/NNS) ,/, (CONJP but/CC also/RB) (NP (ADJP-COOD (ADJP rapid/JJ) ,/, (ADJP non-genomic/JJ)) effects/NNS)) (PP on/IN (NP transmembrane/NN electrolyte/NN movements/NNS))))))))) ./.)
(S (NP-SBJ These/DT) (VP involve/VBP (NP (NP activation/NN) (PP of/IN (NP (NP the/DT sodium\/proton/NN exchanger/NN) (PP of/IN (NP the/DT cell/NN membrane/NN)))) (PP at/IN (NP (NP (ADJP-COOD (ADJP very/RB low/JJ) ,/, (ADJP physiological/JJ)) concentrations/NNS) (PP of/IN (NP aldosterone/NN)))) (PP with/IN (NP (NP an/DT acute/JJ onset/NN) (PP-TMP within/IN (NP (QP 1-2/CD) min/NN)))))) ./.)
(S (NP-SBJ (NP A/DT second/JJ messenger/NN cascade/NN) (VP involved/VBN (NP */-NONE-))) (VP is/VBZ (NP-PRD (NP the/DT inositol/NN 1,4,5-trisphosphate\/calcium/NN pathway/NN) (SBAR (WHNP-1 which/WDT) (S (NP-SBJ *T*-1/-NONE-) (VP responds/VBZ (PP-TMP over/IN (NP the/DT same/JJ rapid/JJ time/NN course/NN))))))) ./.)
(S (NP-SBJ-2 Such/JJ changes/NNS) (ADVP clearly/RB) (VP can/MD not/RB (VP be/VB (VP explained/VBN (NP *-2/-NONE-) (PP by/IN (NP-LGS (NP genomic/JJ mechanisms/NNS) ,/, (SBAR (WHNP-3 which/WDT) (S (NP-SBJ *T*-3/-NONE-) (VP are/VBP (ADJP-PRD responsible/JJ (PP for/IN (NP (NP later/JJ effects/NNS) (PP than/IN (NP the/DT (ADJP (NP membrane/NN) related/JJ) rapid/JJ responses/NNS))))))))))))) ./.)
(S (NP-SBJ-4 (NP The/DT mechanisms/NNS) (VP underlying/VBG (NP (NP these/DT rapid/JJ effects/NNS) (PP of/IN (NP aldosterone/NN)) (PP on/IN (NP electrolytes/NNS))))) (VP have/VBP (VP been/VBN (ADVP extensively/RB) (VP studied/VBN (NP *-4/-NONE-) (PP in/IN (NP (NP human/JJ lymphocytes/NNS) ,/, (SBAR (WHNP-5 which/WDT) (S (ADVP thus/RB) (NP-SBJ *T*-5/-NONE-) (VP may/MD (VP represent/VB (NP (NP valuable/JJ tools/NNS) (PP in/IN (NP (NP the/DT delineation/NN) (PP of/IN (NP (NP the/DT receptor-effector/JJ mechanisms/NNS) (VP involved/VBN (NP */-NONE-)))))))))))))))) ./.)
(S (NP-SBJ (NP The/DT unique/JJ characteristics/NNS) (PP of/IN (NP (NP this/DT new/JJ pathway/NN) (PP for/IN (NP steroid/NN action/NN))))) (VP include/VBP (NP-COOD (NP its/PRP$ rapid/JJ time/NN course/NN) ,/, (NP (NP 10,000-fold/JJ selectivity/NN) (PP for/IN (NP aldosterone/NN)) (PP over/IN (NP cortisol/NN))) and/CC (NP (NP the/DT ineffectiveness/NN) (PP of/IN (NP (NP spironolactones/NNS) ,/, (NP classical/JJ mineralocorticoid/NN antagonists/NNS) ,/,)) (PP as/IN (NP (NP antagonists/NNS) (PP of/IN (NP the/DT response/NN))))))) ./.)
